Clinical trial · Observational
Somatuline Predictive Factors in Acromegaly and NET
Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)
NCT01840449CI-TRIAL-00036507SOPRANocompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acromegaly | — | UNRESOLVED | — |
| Neuroendocrine Tumours | Neuroendocrine Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Somatuline Autogel® 60, 90 or 120 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Neuroendocrine Tumours
- description
- The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
- interventionNames
- Drug: Somatuline Autogel® 60, 90 or 120 mg
- label
- Acromegaly
- description
- The subject will receive treatment as prescribed by the investigator and in accordance with the current recommendations, routine practice and local regulations.
- interventionNames
- Drug: Somatuline Autogel® 60, 90 or 120 mg
Primary outcomes (1)
- measure
- Change in biochemical markers (Growth Hormone [GH] & Insulin-like Growth Factor 1 [IGF-1] in acromegaly subjects and Chromogranin A [CgA] in NET subjects)
- timeFrame
- Baseline and 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Written informed consent (also mandatory in case of retrospective documentation of subject data) * Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on treatment with ATG Exclusion Criteria: * The subject has already been included in this study * Participation in an interventional trial
References
Publications (1)
- DERIVEDRinke A, Maintz C, Muller L, Weber MM, Lahner H, Pavel M, Saeger W, Houchard A, Ungewiss H, Petersenn S. Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Neuroendocrine Tumors in Routine Clinical Practice in Germany and Austria. Exp Clin Endocrinol Diabetes. 2021 Jul;129(7):500-509. doi: 10.1055/a-1342-2755. Epub 2021 Jul 22. PMID 34293802